| P50 | author | Esteban C Nannini | Q39392197 |
| P2093 | author name string | Barbara E Murray | |
| | Kavindra V Singh | |
| | Cesar A Arias | |
| | Vincent H Tam | |
| | Truc T Tran | |
| P2860 | cites work | Real-time in vivo bioluminescent imaging for evaluating the efficacy of antibiotics in a rat Staphylococcus aureus endocarditis model | Q24558684 |
| | Importance of the collagen adhesin ace in pathogenesis and protection against Enterococcus faecalis experimental endocarditis | Q33523801 |
| | Characterization of a chromosomal gene encoding type B beta-lactamase in phage group II isolates of Staphylococcus aureus | Q33703209 |
| | Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model | Q33976444 |
| | Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study | Q34509652 |
| | Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13). | Q41378759 |
| | Importance of beta-lactamase inactivation in treatment of experimental endocarditis caused by Staphylococcus aureus | Q41611983 |
| | Prevalence of blaZ gene types and the cefazolin inoculum effect among methicillin-susceptible Staphylococcus aureus blood isolates and their association with multilocus sequence types and clinical outcome | Q41742134 |
| | In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure | Q41825567 |
| | Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure | Q41961174 |
| | In Vivo Effects of Cefazolin, Daptomycin, and Nafcillin in Experimental Endocarditis with a Methicillin-Susceptible Staphylococcus aureus Strain Showing an Inoculum Effect against Cefazolin | Q42110143 |
| | In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model | Q42627381 |
| | Evaluation of the in vivo efficacy of intramuscularly administered ceftaroline fosamil, a novel cephalosporin, against a methicillin-resistant Staphylococcus aureus strain in a rabbit endocarditis model. | Q42934863 |
| | Cefazolin versus cephalothin in beta-lactamase-producing Staphylococcus aureus endocarditis in a rabbit experimental model | Q44221236 |
| | Cefazolin therapy for Staphylococcus aureus bacteremia | Q46529566 |
| | Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011. | Q46572117 |
| | Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database | Q46607564 |
| | Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms | Q46620675 |
| | Staphylococcal beta-lactamase and efficacy of beta-lactam antibiotics: in vitro and in vivo evaluation. | Q54496342 |
| | Clinical Experiences with Cefazolin and Other Cephalosporins in Bacterial Endocarditis | Q54646847 |
| | Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. | Q55067143 |
| | Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. a | Q57238277 |
| | 6 Immunological techniques for studying β-lactamases | Q66895658 |
| | Unsuccessful Treatment of Staphylococcal Endocarditis With Cefazolin | Q67020666 |
| | Differentiation of beta-lactamase variants of Staphylococcus aureus by substrate hydrolysis profiles | Q69734960 |
| | Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? | Q82441020 |
| | Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target | Q34510488 |
| | Comparison of in vivo and in vitro pharmacodynamics of a humanized regimen of 600 milligrams of Ceftaroline Fosamil every 12 hours against Staphylococcus aureus at initial inocula of 106 and 108 CFU per milliliter | Q34596470 |
| | PBP2a mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. | Q34596507 |
| | Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens | Q34699108 |
| | Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections | Q34922533 |
| | Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates | Q35191501 |
| | Use of extracts versus whole-cell bacterial suspensions in the identification of Staphylococcus aureus beta-lactamase variants | Q35250211 |
| | Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model | Q35276965 |
| | Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia? | Q35364152 |
| | Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia | Q35408518 |
| | Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects | Q35746176 |
| | Prevalence of blaZ gene types and the inoculum effect with cefazolin among bloodstream isolates of methicillin-susceptible Staphylococcus aureus. | Q36171547 |
| | Comparable Effectiveness of First Week Treatment with Anti-Staphylococcal Penicillin versus Cephalosporin in Methicillin-Sensitive Staphylococcus aureus Bacteremia: A Propensity-Score Adjusted Retrospective Study | Q36206847 |
| | Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model | Q36396172 |
| | Difference in susceptibility to gram-negative urinary tract infection between C3H/HeJ and C3H/HeN mice | Q37043190 |
| | Importance of the ebp (endocarditis- and biofilm-associated pilus) locus in the pathogenesis of Enterococcus faecalis ascending urinary tract infection | Q37187112 |
| | Cefazolin high-inoculum effect in methicillin-susceptible Staphylococcus aureus from South American hospitals. | Q37286901 |
| | Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia | Q37335859 |
| | Clinical outcomes with rapid detection of methicillin-resistant and methicillin-susceptible Staphylococcus aureus isolates from routine blood cultures | Q37336290 |
| | Targeting pili in enterococcal pathogenesis | Q37713275 |
| | Serious infections caused by methicillin-resistant Staphylococcus aureus | Q37781817 |
| | Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus | Q37861942 |
| | MRSA: the first half century | Q37947249 |
| | Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections | Q38025132 |
| | Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia | Q38117077 |
| | Antistaphylococcal penicillins versus cephalosporins for definitive treatment of meticillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis | Q38259798 |
| | β-Lactam Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Comparative Review of Cefazolin versus Antistaphylococcal Penicillins | Q39051288 |
| | Single- and Repeated-Dose Pharmacokinetics of Ceftaroline in Plasma and Soft Tissues of Healthy Volunteers for Two Different Dosing Regimens of Ceftaroline Fosamil | Q39226965 |
| | Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus | Q39566665 |
| | BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis | Q39650937 |
| | Indomethacin injury to the rat small intestine is dependent upon biliary secretion and is associated with overgrowth of enterococci | Q39710654 |
| | Efficacy of ticarcillin-clavulanic acid for treatment of experimental Staphylococcus aureus endocarditis in rats | Q39867979 |
| | Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible Staphylococcus aureus | Q40336487 |
| | Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue | Q40548386 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| | cefazolin | Q415739 |
| P577 | publication date | 2017-06-27 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Efficacy of Ceftaroline against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of Endocarditis | |
| P478 | volume | 61 | |